Therapeutic Antibodies

#Alzheimer's #Cancer immunotherapy #Cancer research #Dermatology #Drug development #Drug discovery #Genetics / genomics #Immunology / Virology & Vaccines #Immunotherapy #Monoclonal antibodies #mRNA

This week in drug discovery (12-16 December)

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. The focus has been on immunotherapy and genetics this week, with exciting developments in the treatment of multiple myeloma, atopic dermatitis, Alzheimer’s, late-stage melanoma and acute myeloid leukaemia.  The top stories: … Read More

#News

Scientist in laboratory
#Antibodies #Cancer immunotherapy #Cancer research #Clinical trials #Immunotherapy #Janssen #Leukaemia #Myeloma #Oncology

New trial data revealed in potential myeloma and leukaemia treatments

Jannsen has revealed clinical trial results for its pipeline of products to treat multiple myeloma and leukaemia.  The findings were presented at the American Society of Hematology (ASH) 2022 Annual Meeting taking place in New Orleans, US.  Along with positive Phase… Read More

#Cancer Research #News

A woman scratching her skin
#Antibodies #Atopic dermatitis #Dermatology #Immunotherapy #Monoclonal antibodies

New dermatitis treatment shows promising long-term results

A novel, patient-tailored monoclonal antibody therapy has shown promise in treating moderate to severe atopic dermatitis.  Patients who participated in a clinical trial of rocatinlimab showed positive results while taking the drug and up to 20 weeks after stopping therapy, Mount Sinai researchers have… Read More

#News #Trending News

Human antibodies
#Antibodies #Immunotherapy #Investment #Start-ups

Start-up focusses on human-derived antibody drugs

Biotechnology company Infinimmune has closed a $12 million seed round to focus on human-derived antibody drugs. The seed funding was led by Playground Global, with participation from Pear VC, Civilization Ventures, Axial VC, Ron Alfa, Jacob Becraft, Paul Conley, and Joshua Meier. “The industry has proven the value of antibody-based… Read More

#News #Start-up Zone

IgE antibody
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

Exclusive webinar: Harness the power of IgE antibodies

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More

Webinar date:
Brought to you by SPT Labtech
#Editor's Choice #News

HIV vaccine
#Antibodies #HIV #mRNA-based vaccines #Phase I trial

Encouraging trial findings renew hope for HIV vaccine

While scientists have struggled in the past to create an effective vaccine against HIV, a novel vaccine design strategy shows new promise, according to data from a first-in-human clinical trial.  In a paper published in Science, the researchers reveal critical new insights… Read More

#News #Trending News

Antibodies attacking virus
#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

Last chance to register: How to accelerate antibody discovery

Download the webinar Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director of Product Management,… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

IgE antibody
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

The power of IgE antibodies in creating novel therapeutics

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More

Webinar date:
Brought to you by SPT Labtech
#News

Antibodies
#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

Learn how to accelerate antibody discovery: webinar

Download the exclusive event: Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director of… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

Heart attack patient with doctor
#Heart attack #Monoclonal antibodies #Phase II trial

UK trial will test new mAb treatment in heart attack patients

A potential new drug to improve the long-term outcomes for heart attack patients will be trialled in the UK under a new agreement.  The Phase IIb LIBERATE study will test the tolerance and the efficacy of glenzocimab 1000mg to reduce heart damage following a myocardial infarction (MI). Read More

#News

Cell culture media
#Biologics #Bioproduction #Cell and gene therapy #Cell therapy #Life sciences #Manufacturing

Fujifilm expands cell culture media manufacturing

Fujifilm Corporation has announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA.  The new site will be operated by Fujifilm Irvine Scientific, a manufacturer of cell culture solutions for life science research, bioproduction, cell therapy… Read More

#News

IgE antibodies
#Allergy #Antibody discovery workflow #Engineered antibodies #Genomics #IgE antibodies #Immunotherapy #Monoclonal antibodies

Learn how to harness the power of IgE antibodies

Watch the webinar Harnessing the power of IgE antibodies to create novel therapeutics supported by SPT Labtech. From human B cells to engineered antibodies, IgGenix is taking a novel approach towards breaking through the last frontier of immunology: allergies. By reengineering key antibodies in the allergic cascade, this… Read More

Webinar date:
Brought to you by SPT Labtech
#News

CST antibodies using the Cell DIVE multiplexed imaging solution
#Antibodies #Biomarkers #Cancer research #Collaboration #Drug discovery #Partnership

New antibody validation partnership hopes to “power scientific discovery” 

Leica Microsystems and Cell Signaling Technology (CST) have agreed a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution.  As an open multiplexing system, Cell DIVE allows researchers to design custom antibody biomarker panels.  James O’Brien, Vice President Life Sciences at Leica Microsystems, said: “Instead of spending… Read More

#Business & Investment #News

Antibodies
#Antibody discovery workflow #B cell diversity #Monoclonal antibodies

Exclusive webinar: how to accelerate antibody discovery

Download the exclusive free event: Accessing Broad B Cell Diversity to Rapidly Identify High-Value Rabbit Monoclonal Antibodies. Opto B Discovery on the Beacon optofluidic system is designed to enable rapid selection of lead candidates by function-forward screening of B cells in under one week. Anupam Singhal, Director… Read More

Webinar date:
Brought to you by Berkeley Lights
#Editor's Choice #News

#Biologics #Biotechnology #Funding #Seed funding #Therapeutics

How will $41 million be used to fight chronic and age-related diseases? 

Juvena Therapeutics, a biotechnology company scaling a computational platform to map the therapeutic potential of secreted proteins, has raised $41 million in an oversubscribed Series A, bringing its total funding to $50 million. The new funding will power the expansion of Juvena’s drug discovery platform and advance the company’s biologics… Read More

#Business & Investment #News